Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00549549 · ClinicalTrials.gov registry record · Phase 3
Celebrex In Acute Gouty Arthritis Study
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT00549549 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 402 participants.
The verdict
NCT00549549, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.
Interventions
- DRUG Celecoxib
- DRUG Indomethacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00549549
The ClinicalTrials.gov registry entry for NCT00549549 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT00549549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00549549 about?
NCT00549549 is a clinical study titled "Celebrex In Acute Gouty Arthritis Study". This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.
What is the current status of trial NCT00549549?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2008-02. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00549549?
The interventions under investigation include: Celecoxib (DRUG), Indomethacin (DRUG).
Who is sponsoring clinical trial NCT00549549?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.